Vidac Pharma Holding PLC: Commencement of Trading on Xetra

Enhancement of Visibility and Access to European Investors

London (pta027/15.12.2025/15:00 UTC+1)

London, UK– 15 December 2025 – Vidac Pharma Holdings Plc., Vidac Pharma Holdings Plc., (XETRA, Dusseldorf, Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) a clinical-stage biopharmaceutical company focused on the development of first-in-class oncology therapies, is pleased to announce that its ordinary shares are now being traded on Xetra, the electronic trading platform operated by Deutsche Börse.

Dr. Max Herzberg, Active Chairman & CEO of Vidac Pharma Holdings Plc, commented:

"The commencement of trading on Xetra represents an important milestone for Vidac Pharma. It increases our visibility within the European capital markets and improves access for a broader base of institutional and private investors as we continue to advance our clinical development programs."

The commencement of trading on Xetra provides Vidac Pharma with enhanced exposure among European investors and complements the Company's existing trading arrangements by supporting liquidity and accessibility. The Board of Directors believes that trading on Xetra aligns with Vidac Pharma's long-term strategy and reflects the Company's continued progress as it advances its oncology pipeline.

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase-2 metabolic checkpoint (HK2) in cancer cells to renormalize the tumor microenvironment and selectively provoke programmed cell death without affecting surrounding normal tissue. VDA-1102, Vidac Pharma's first drug candidate, has demonstrated effectiveness against advanced Actinic Keratosis (AK), while interim Phase 2 results in Cutaneous T-Cell Lymphoma (CTCL) have shown promising clinical benefit in humans.

Important Information

The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding Plc, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "may," "will," "plans," "continue," "ongoing," "potential," "predict," "project," "target," "seek," or "should," and include statements the Company makes concerning the intended results of its strategy.
By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf (Primärmarkt), Hamburg, Stuttgart